Home » Stocks » SONN

Sonnet BioTherapeutics Holdings, Inc. (SONN)

Stock Price: $2.67 USD 0.02 (0.75%)
Updated Jan 21, 2021 4:00 PM EST - Market closed
After-hours: $2.72 +0.05 (1.87%) Jan 21, 7:42 PM
Market Cap 45.86M
Revenue (ttm) n/a
Net Income (ttm) -65.60M
Shares Out 9.42M
EPS (ttm) -6.96
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 21
Last Price $2.67
Previous Close $2.65
Change ($) 0.02
Change (%) 0.75%
Day's Open 2.70
Day's Range 2.62 - 2.73
Day's Volume 1,170,977
52-Week Range 0.34 - 7.99


Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
GuruFocus - 1 month ago

Wall Street recommends buying shares of Sonnet BioTherapeutics Holdings Inc. (NASDAQ:SONN) and Sigma Labs Inc. (NASDAQ:SGLB), which you would not expect after these 2 stocks performed so poorl...

Other stocks mentioned: SGLB
Accesswire - 1 month ago

PRINCETON, NJ / ACCESSWIRE / December 17, 2020 / Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) ("Sonnet" or the "Company"), a biopharmaceutical company developing innovative targeted bio...

InvestorPlace - 4 months ago

The pandemic highlights how far medical science has come. It also highlights how exciting the future is.

Other stocks mentioned: ADMA, AZN, BNTX, CERS, LMNL, PFE
Benzinga - 4 months ago

Health care stocks levered to blood collection and sampling, and plasma therapy biopharma companies are getting a big boost Monday after the FDA issued emergency use authorization for the use ...

Other stocks mentioned: ADMA, CERS, GRFS, KMDA, LMNL, THMO, TTOO
Benzinga - 4 months ago

The U.S. Food and Drug Administration issued an emergency use authorization (EUA) for investigational convalescent plasma for the treatment of COVID-19 in hospitalized patients as part of the ...

Other stocks mentioned: KMDA, LMNL
Benzinga - 9 months ago

Sonnet BioTherapeutics Holdings, Inc. (NASDAQ: SONN) were down 11% on Wednesday after skyrocketing 56.9% on Tuesday on COVID-19-related news.

About SONN

Sonnet BioTherapeutics Holdings, an oncology-focused biotechnology company, develops platform for biologic medicines of single or bispecific action. The company develops fully human albumin binding (FHAB) technology, which utilizes human single chain antibodies fragment that binds to and hitch-hikes on human serum albumin for transport to target tissues. Its lead candidate includes SON-080, a human version of low dose Interleukin-6 (IL-6), which has completed Phase I trials for the treatment of patients with chemotherapy-induced peripheral neur... [Read more...]

Michael Pruitt
Stock Exchange
Ticker Symbol
Full Company Profile

Financial Performance

Financial Statements